The Fountain of Youth by Targeting Senescent Cells?

Trends in Molecular Medicine

Volumn 23, Issue 1, 2017, Pages 6-17

  de Keizer, Peter L J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

aging; FOXO; reprogramming; senescence; therapy

Indexed keywords

CELL PENETRATING PEPTIDE; TRANSCRIPTION FACTOR FOXO; FORKHEAD TRANSCRIPTION FACTOR;

CELL AGING; CLEARANCE; DISEASES; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HEALTH; HUMAN; INTRACELLULAR SIGNALING; META ANALYSIS (TOPIC); MOLECULAR PATHOLOGY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REJUVENATION; REVIEW; SENESCENCE; TISSUE REPAIR; AGING; ANIMAL; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SIGNAL TRANSDUCTION;

AGING; ANIMALS; CELL AGING; CELL-PENETRATING PEPTIDES; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION;

EID: 85007351303     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2016.11.006     Document Type: Review

References (95)

1. 1 Lopez-Otin, C., et al. The hallmarks of aging. Cell 153 (2013), 1194–1217.
2. 2 Vaupel, J.W., Biodemography of human ageing. Nature 464 (2010), 536–542.
3. 3 Muñoz-Espín, D., Serrano, M., Cellular senescence: from physiology to pathology. Nat. Rev. Mol. Cell Biol. 15 (2014), 482–496.
4. 4 Tinkum, K.L., et al. Bioluminescence imaging captures the expression and dynamics of endogenous p21 promoter activity in living mice and intact cells. Mol. Cel. Biol. 31 (2011), 3759–3772.
5. 5 Baker, D.J., et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 479 (2011), 232–236.
6. 6 Burd, C.E., et al. Monitoring tumorigenesis and senescence in vivo with a p16(INK4a)-luciferase model. Cell 152 (2013), 340–351.
7. 7 Demaria, M., et al. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Dev. Cell 31 (2014), 722–733.
8. 8 Ohtani, N., et al. Visualizing the dynamics of p21(Waf1/Cip1) cyclin-dependent kinase inhibitor expression in living animals. Proc. Natl. Acad. Sci. U.S.A. 104 (2007), 15034–15039.
9. 9 Yamakoshi, K., et al. Real-time in vivo imaging of p16Ink4a reveals cross talk with p53. J. Cell Biol. 186 (2009), 393–407.
10. 10 Baker, D.J., et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature 530 (2016), 184–189.
11. 11 Serrano, M., et al. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88 (1997), 593–602.
12. 12 Brown, J.P., et al. Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science 277 (1997), 831–834.
13. 13 Coppe, J.P., et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 6 (2008), 2853–2868.
14. 14 Kuilman, T., et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133 (2008), 1019–1031.
15. 15 Acosta, J.C., et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133 (2008), 1006–1018.
16. 16 McCawley, L.J., et al. Keratinocyte expression of MMP3 enhances differentiation and prevents tumor establishment. Am. J. Pathol. 173 (2008), 1528–1539.
17. 17 Villeda, S.A., et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 477 (2011), 90–94.
18. 18 Franckhauser, S., et al. Overexpression of Il6 leads to hyperinsulinaemia, liver inflammation and reduced body weight in mice. Diabetologia 51 (2008), 1306–1316.
19. 19 Storer, M., et al. Senescence is a developmental mechanism that contributes to embryonic growth and patterning. Cell 155 (2013), 1119–1130.
20. 20 Munoz-Espin, D., et al. Programmed cell senescence during mammalian embryonic development. Cell 155 (2013), 1104–1118.
21. 21 Niedernhofer, L.J., et al. A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis. Nature 444 (2006), 1038–1043.
22. 22 Vermeij, W.P., et al. Restricted diet delays accelerated ageing and genomic stress in DNA-repair-deficient mice. Nature 537 (2016), 427–431.
23. 23 Barnhoorn, S., et al. Cell-autonomous progeroid changes in conditional mouse models for repair endonuclease XPG deficiency. PLoS Genet., 10, 2014, e1004686.
24. 24 Murai, M., et al. Early postnatal ataxia and abnormal cerebellar development in mice lacking xeroderma pigmentosum group A and Cockayne syndrome group B DNA repair genes. Proc. Natl. Acad. Sci. U.S.A. 98 (2001), 13379–13384.
25. 25 de Boer, J., et al. A mouse model for the basal transcription/DNA repair syndrome trichothiodystrophy. Mol. Cell 1 (1998), 981–990.
26. 26 de Boer, J., et al. Premature aging in mice deficient in DNA repair and transcription. Science 296 (2002), 1276–1279.
27. 27 Wijnhoven, S.W., et al. Accelerated aging pathology in ad libitum fed Xpd(TTD) mice is accompanied by features suggestive of caloric restriction. DNA Repair (Amst) 4 (2005), 1314–1324.
28. 28 Wiley, C.D., et al. Mitochondrial dysfunction induces senescence with a distinct secretory phenotype. Cell Metab. 23 (2016), 303–314.
29. 29 Krizhanovsky, V., et al. Senescence of activated stellate cells limits liver fibrosis. Cell 134 (2008), 657–667.
30. 30 Krishnamurthy, J., et al. Ink4a/Arf expression is a biomarker of aging. J. Clin. Invest. 114 (2004), 1299–1307.
31. 31 Ferrucci, L., et al. The origins of age-related proinflammatory state. Blood 105 (2005), 2294–2299.
32. 32 Starr, M.E., et al. Age-associated increase in cytokine production during systemic inflammation: adipose tissue as a major source of IL-6. J. Gerontol. A Biol. Sci. Med. Sci. 64 (2009), 723–730.
33. 33 Steiner, M.K., et al. Interleukin-6 overexpression induces pulmonary hypertension. Circ. Res. 104 (2009), 236–244.
34. 34 Franceschi, C., Campisi, J., Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J. Gerontol. A Biol. Sci. Med. Sci. 69:Suppl 1 (2014), S4–S9.
35. 35 Baker, D.J., et al. Opposing roles for p16Ink4a and p19Arf in senescence and ageing caused by BubR1 insufficiency. Nat. Cell Biol. 10 (2008), 825–836.
36. 36 Gregg, S.Q., et al. A mouse model of accelerated liver aging caused by a defect in DNA repair. Hepatology 55 (2012), 609–621.
37. 37 Zhu, Y., et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 14 (2015), 644–658.
38. 38 Chang, J., et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat. Med. 22 (2016), 78–83.
39. 39 Yosef, R., et al. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat. Commun., 7, 2016, 11190.
40. 40 Chondrogianni, N., et al. Anti-ageing and rejuvenating effects of quercetin. Exp. Gerontol. 45 (2010), 763–771.
41. 41 Talpaz, M., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354 (2006), 2531–2541.
42. 42 Rudin, C.M., et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin. Cancer Res. 18 (2012), 3163–3169.
43. 43 Tait, S.W., Green, D.R., Mitochondria and cell death: outer membrane permeabilization and beyond. Nat. Rev. Mol. Cell Biol. 11 (2010), 621–632.
44. 44 Evans, J.D., et al. Detailed tissue expression of bcl-2, bax, bak and bcl-x in the normal human pancreas and in chronic pancreatitis, ampullary and pancreatic ductal adenocarcinomas. Pancreatology 1 (2001), 254–262.
45. 45 Alireza, A., et al. An immunohistochemistry study of tissue bcl-2 expression and its serum levels in breast cancer patients. Ann. N. Y. Acad. Sci. 1138 (2008), 114–120.
46. 46 Schoenwaelder, S.M., et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 118 (2011), 1663–1674.
47. 47 Wilson, W.H., et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 11 (2010), 1149–1159.
48. 48 Schmid, D., et al. Nanoencapsulation of ABT-737 and camptothecin enhances their clinical potential through synergistic antitumor effects and reduction of systemic toxicity. Cell Death Dis., 5, 2014, e1454.
49. 49 Kaefer, A., et al. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia. Cancer Chemother. Pharmacol. 74 (2014), 593–602.
50. 1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev. 8 (1994), 2540–2551.
51. 51 Galanos, P., et al. Chronic p53-independent p21 expression causes genomic instability by deregulating replication licensing. Nat. Cell Biol. 18 (2016), 777–789.
52. 52 Correia-Melo, C., et al. Mitochondria are required for pro-ageing features of the senescent phenotype. EMBO J. 35 (2016), 724–742.
53. 53 Coppe, J.P., et al. Tumor suppressor and aging biomarker p16(INK4a) induces cellular senescence without the associated inflammatory secretory phenotype. J. Biol. Chem. 286 (2011), 36396–36403.
54. 54 Hunter, C.A., Jones, S.A., IL-6 as a keystone cytokine in health and disease. Nat. Immunol. 16 (2015), 448–457.
55. 55 Di Paolo, N.C., Shayakhmetov, D.M., Interleukin 1alpha and the inflammatory process. Nat. Immunol. 17 (2016), 906–913.
56. 56 Narita, M., et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113 (2003), 703–716.
57. 57 Kosar, M., et al. Senescence-associated heterochromatin foci are dispensable for cellular senescence, occur in a cell type- and insult-dependent manner and follow expression of p16(ink4a). Cell Cycle 10 (2011), 457–468.
58. 58 Davalos, A.R., et al. p53-dependent release of alarmin HMGB1 is a central mediator of senescent phenotypes. J. Cell Biol. 201 (2013), 613–629.
59. 59 Pluquet, O., et al. The unfolded protein response and cellular senescence. A review in the theme: cellular mechanisms of endoplasmic reticulum stress signaling in health and disease. Am. J. Physiol. Cell Physiol. 308 (2015), C415–C425.
60. 60 Young, A.R., et al. Autophagy mediates the mitotic senescence transition. Genes Dev. 23 (2009), 798–803.
61. 61 Narita, M., Young, A.R., Autophagy facilitates oncogene-induced senescence. Autophagy 5 (2009), 1046–1047.
62. 62 Laberge, R.M., et al. MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat. Cell Biol. 17 (2015), 1049–1061.
63. 63 Herranz, N., et al. mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype. Nat. Cell Biol. 17 (2015), 1205–1217.
64. 64 Pietras, E.M., et al. Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal. Nat. Cell Biol. 18 (2016), 607–618.
65. 65 Orjalo, A.V., et al. Cell surface-bound IL-1alpha is an upstream regulator of the senescence-associated IL-6/IL-8 cytokine network. Proc. Natl. Acad. Sci. U.S.A. 106 (2009), 17031–17036.
66. 66 Brady, J.J., et al. Early role for IL-6 signalling during generation of induced pluripotent stem cells revealed by heterokaryon RNA-Seq. Nat. Cell Biol. 15 (2013), 1244–1252.
67. 67 Cahu, J., et al. Senescence-associated secretory phenotype favors the emergence of cancer stem-like cells. Cell Death Dis., 3, 2012, e446.
68. 68 Chang, T.S., et al. Activation of IL6/IGFIR confers poor prognosis of HBV-related hepatocellular carcinoma through induction of OCT4/NANOG expression. Clin. Cancer Res. 21 (2015), 201–210.
69. 69 Medema, R.H., et al. AFX-like forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 404 (2000), 782–787.
70. 70 Salih, D.A., Brunet, A., FoxO transcription factors in the maintenance of cellular homeostasis during aging. Curr. Opin. Cell Biol. 20 (2008), 126–136.
71. 71 de Keizer, P.L., et al. Forkhead box O as a sensor, mediator, and regulator of redox signaling. Antioxid. Redox Signal. 14 (2011), 1093–1106.
72. 72 Eijkelenboom, A., Burgering, B.M., FOXOs: signalling integrators for homeostasis maintenance. Nat. Rev. Mol. Cell Biol. 14 (2013), 83–97.
73. 73 Chung, Y.M., et al. FOXO3 signalling links ATM to the p53 apoptotic pathway following DNA damage. Nat. Commun., 3, 2012, 1000.
74. 74 de Keizer, P.L., et al. Activation of forkhead box O transcription factors by oncogenic BRAF promotes p21cip1-dependent senescence. Cancer Res. 70 (2010), 8526–8536.
75. 75 Martinez, L.A., et al. p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis 23 (2002), 1289–1296.
76. 76 Jackson, J.G., et al. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell 21 (2012), 793–806.
77. 77 Hong, H., et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 460 (2009), 1132–1135.
78. 78 Tschaharganeh, D.F., et al. p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer. Cell 158 (2014), 579–592.
79. 79 Nakae, J., et al. The forkhead transcription factor Foxo1 regulates adipocyte differentiation. Dev. Cell 4 (2003), 119–129.
80. 80 Essers, M.A., et al. Functional interaction between beta-catenin and FOXO in oxidative stress signaling. Science 308 (2005), 1181–1184.
81. 81 Hoogeboom, D., et al. Interaction of FOXO with beta-catenin inhibits beta-catenin/T cell factor activity. J. Biol. Chem. 283 (2008), 9224–9230.
82. 82 McClelland Descalzo, D.L., et al. Glucose-induced oxidative stress reduces proliferation in embryonic stem cells via FOXO3A/beta-catenin-dependent transcription of p21(cip1). Stem Cell Reports 7 (2016), 55–68.
83. 83 Wang, F., et al. Biochemical and structural characterization of an intramolecular interaction in FOXO3a and its binding with p53. J. Mol. Biol. 384 (2008), 590–603.
84. 84 Lönn, P., Dowdy, S.F., Cationic PTD/CPP-mediated macromolecular delivery: charging into the cell. Expert Opin. Drug Deliv. 12 (2015), 1627–1636.
85. 85 Herce, H.D., Garcia, A.E., Molecular dynamics simulations suggest a mechanism for translocation of the HIV-1 TAT peptide across lipid membranes. Proc. Natl. Acad. Sci. U.S.A. 104 (2007), 20805–20810.
86. 86 Jones, A.T., Sayers, E.J., Cell entry of cell penetrating peptides: tales of tails wagging dogs. J. Control. Release 161 (2012), 582–591.
87. 87 Kruiswijk, F., et al. Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling. Oncogene 35 (2016), 2166–2177.
88. 88 Borsello, T., et al. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat. Med. 9 (2003), 1180–1186.
89. 89 Beydoun, T., et al. Subconjunctival injection of XG-102, a JNK inhibitor peptide, in patients with intraocular inflammation: a safety and tolerability study. J. Ocul. Pharmacol. Ther. 31 (2015), 93–99.
90. 90 Deloche, C., et al. XG-102 administered to healthy male volunteers as a single intravenous infusion: a randomized, double-blind, placebo-controlled, dose-escalating study. Pharmacol. Res. Perspect., 2, 2014, e00020.
91. 91 Suckfuell, M., et al. Efficacy and safety of AM-111 in the treatment of acute sensorineural hearing loss: a double-blind, randomized, placebo-controlled phase II study. Otol. Neurotol. 35 (2014), 1317–1326.
92. 92 Warso, M.A., et al. A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours. Br. J. Cancer 108 (2013), 1061–1070.
93. 93 Filonov, G.S., et al. Bright and stable near-infrared fluorescent protein for in vivo imaging. Nat. Biotechnol. 29 (2011), 757–761.
94. 94 Ritsma, L., et al. Intestinal crypt homeostasis revealed at single-stem-cell level by in vivo live imaging. Nature 507 (2014), 362–365.
95. 95 Mosteiro, L., et al. Tissue damage and senescence provide critical signals for cellular reprogramming in vivo. Science, 354, 2016, 10.1126/science.aaf4445 Published online November 25, 2016.